Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Viatris Swats Away Concerns Over Divestment Valuations

Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.

Strategy Deals

ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead

ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.

Sales & Earnings Launches

Viatris Slashes Full-Year Revenue Guidance By $800m

Viatris is committing to earlier EBITDA and free cash flow targets for 2022, although it now expects to lose a chunk of revenues for the full year amid severe and sustained foreign currency exposure.

Sales & Earnings Strategy
See All

Deals Explore this Topic

Set Alert for Deals

Viatris Swats Away Concerns Over Divestment Valuations

Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.

Strategy Deals

Hikma Will Push Harder To Make M&A Happen

Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.

Strategy M & A

MPP Strikes Long-Acting Injectable Cabotegravir Deal For HIV PrEP

After the Medicines Patent Pool secured a licensing deal with Viiv Healthcare for long-acting injectable cabotegravir for HIV pre-exposure prophylaxis, prospective generic sub-licensees have until 4 September to submit expressions of interest.

Deals Intellectual Property
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

EMA To Update Active Substances Guide To Address Nitrosamine Contamination

The European Medicines Agency wants to make it clearer for drug sponsors what more they can do to address the presence of cancer-causing impurities in active substances, and how to deal with the issue in their regulatory submissions.

Manufacturing Regulation

Kabi Awaits Melrose Park Fate As mAbxience Deal Closes

Fresenius Kabi is pressing on with its ‘Vision 2026’ strategic growth initiatives, with the company wrapping up its acquisition of Insud Pharma’s bio unit mAbxience. However, it remains “to some degree output constrained,” which looks set to continue to impact operations, amid staff shortages.

Biosimilars M & A

Inflation And COVID Put Pressure On Europe’s Paracetamol Supply Chain

Inflation, new COVID-19 waves and delayed cold and flu outbreaks are causing disruption to Europe's paracetamol supply chain. Industry is not currently concerned, but regulators, for example in France, are introducing measures to prevent this issue spreading from children's to adult forms of the drug, as well as to ibuprofen-based alternatives.

Supply Chain Generic Drugs
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead

ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.

Sales & Earnings Launches

Viatris Slashes Full-Year Revenue Guidance By $800m

Viatris is committing to earlier EBITDA and free cash flow targets for 2022, although it now expects to lose a chunk of revenues for the full year amid severe and sustained foreign currency exposure.

Sales & Earnings Strategy

Amneal Expects Host Of New Launches To Drive Firm To Success

Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.

Sales & Earnings Launches

People Explore this Topic

Set Alert for People

Hikma Will Push Harder To Make M&A Happen

Following a challenging first half for Hikma, executive chairman and CEO Said Darwazah talks to Generics Bulletin about how the firm is planning to be more active in making deals happen, as well as how it plans to address pressures on its Generics division that led to two consecutive downgrades in guidance this year.

Strategy M & A

Who’s Hired? Makov To Step Away From Sun Pharma After 10 Years

While Israel Makov steps away from Sun Pharmaceuticals, Mayne and Avet bring in new executives, Amneal appoints a new director and the AAM promotes a loyal colleague.

Executive Changes Leadership

Generics Bulletin Editor’s Picks For Q2 2022

Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.

Biosimilars Generic Drugs
See All
UsernamePublicRestriction

Register